Review article: Chemoprevention of colorectal cancer

Alimentary Pharmacology and Therapeutics

Volumn 19, Issue 1, 2004, Pages 1-24

  Courtney, E D J ^a   Melville, D M ^b   Leicester, R J ^b  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CALCIUM; CALCIUM CARBONATE; CELECOXIB; CURCUMIN; CYCLOOXYGENASE 2 INHIBITOR; CYTOCHROME P450; EFLORNITHINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; FOLIC ACID; GALACTOSE; GEFITINIB; GLUCURONOSYLTRANSFERASE; ICOSAPENTAENOIC ACID; LYSINE ACETYLSALICYLATE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; ORNITHINE DECARBOXYLASE; PELITINIB; PIROXICAM; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RESVERATROL; SELENIUM; SULINDAC; URSODEOXYCHOLIC ACID;

ACNE; ADENOMA; ADENOMATOUS POLYP; AUDIOTOXICITY; CALCIUM INTAKE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PREVENTION; CANCER RECURRENCE; CANCER RISK; CANCER SCREENING; CANCER SUSCEPTIBILITY; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COLORECTAL CANCER; COLORECTAL TUMOR; DIARRHEA; DIET SUPPLEMENTATION; DIETARY FIBER; DIETARY INTAKE; DISEASE MARKER; DNA POLYMORPHISM; DOSE RESPONSE; DRUG ACTIVITY; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG TARGETING; DRUG TOLERABILITY; ENZYME POLYMORPHISM; FAMILY HISTORY; FOLATE METABOLISM; FOLIC ACID DEFICIENCY; GASTROINTESTINAL HEMORRHAGE; GENE MUTATION; GENETIC VARIABILITY; HUMAN; LIFE EXPECTANCY; LIFESTYLE; LONG TERM CARE; MASS SCREENING; META ANALYSIS; METHODOLOGY; NONHUMAN; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RASH; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; SIDE EFFECT; STROKE; THROMBOCYTOPENIA; TOXICITY; TREATMENT OUTCOME; TREATMENT PLANNING; VITAMIN SUPPLEMENTATION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CALCIUM; CHEMOPREVENTION; COLORECTAL NEOPLASMS; CYCLOOXYGENASE INHIBITORS; DIETARY FIBER; EFLORNITHINE; FOLIC ACID; HUMANS; LIFE EXPECTANCY; MASS SCREENING; RECEPTOR, EPIDERMAL GROWTH FACTOR; SELENIUM; URSODEOXYCHOLIC ACID;

EID: 1642451775     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01806.x     Document Type: Review

References (165)

1. Hakama M. Chemoprevention of cancer. Acta Oncol 1998; 37: 227-30.
2. Hayne D, Brown RS, McCormack M, Quinn MJ, Payne HA, Babb P. Current trends in colorectal cancer: site, incidence, mortality and survival in England and Wales. Clin Oncol 2001; 13: 448-52.
3. Ilyas M, Straub J, Tomlinson IP, Bodmer WF. Genetic pathways in colorectal and other cancers. Eur J Cancer 1999; 35: 335-51.
4. Atkin WS, Northover JM. Population based endoscopic screening for colorectal cancer. Gut 2003; 52: 321-2.
5. UK Flexible Sigmoidoscopy Screening Trial Investigators. Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomised trial. Lancet 2002; 359: 1291-300.
6. Macafee DA, Scholefield JH. Population based endoscopic screening for colorectal cancer. Gut 2003; 52: 323-6.
7. McCallion K, Mitchell RM, Wilson RH, et al. Flexible sigmoidoscopy and the changing distribution of colorectal cancer: implications for screening. Gut 2001; 48: 522-5.
8. Rembacken BJ, Fujii T, Cairns A, et al. Flat and depressed colonic neoplasms: a prospective study of 1000 colonos-copies in the UK. Lancet 2000; 355: 1211-4.
9. Levin B. Potential pitfalls in the use of surrogate endpoints in colorectal adenoma chemoprevention. J Natl Cancer Inst 2003; 95: 697-9.
10. Schatzkin A, Gail M. The promise and peril of surrogate end points in cancer research. Nature Rev Cancer 2002; 2: 19-27.
11. Einspahr JG, Alberts DS, Gapstur SM, Bostick RM, Emerson SS, Gerner EW. Surrogate end-point biomarkers as measures of colon cancer risk and their use in cancer chemoprevention trials. Cancer Epidemiol Biomark Prev 1997; 6: 37-48.
12. Atkin WS, Morson BC, Cuzick J. Long-term risk of colorectal cancer after excision of rectosigmoid adenomas. N Engl J Med 1992; 326: 658-62.
13. Winawer SJ, Zauber AG, Ho MN, et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 1993; 329: 1977-81.
14. Mandel JS, Church TR, Bond JH, et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 2000; 343: 1603-7.
15. Eide TJ. Risk of colorectal cancer in adenoma-bearing individuals within a defined population. Int J Cancer 1986; 38: 173-6.
16. Hixson LJ, Fennerty MB, Sampliner RE, McGee D, Garewal H. Prospective study of the frequency and size distribution of polyps missed by colonoscopy. J Natl Cancer Inst 1990; 82: 1769-72.
17. Rex DK, Cutler CS, Lemmel GT, et al. Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies. Gastroenterology 1997; 112: 24-8.
18. Winawer SJ, Stewart ET, Zauber AG, et al. A comparison of colonoscopy and double-contrast barium enema for surveillance after polypectomy. National Polyp Study Work Group. N Engl J Med 2000; 342: 1766-72.
19. Hill MJ. Molecular and clinical risk markers in colon cancer trials. Eur J Cancer 2000; 36: 1288-91.
20. Giovannucci E, Egan KM, Hunter DJ, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995; 333: 609-14.
21. Garcea G, Sharma RA, Dennison A, Steward WP, Gescher A, Berry DP. Molecular biomarkers of colorectal carcinogenesis and their role in surveillance and early intervention. Eur J Cancer 2003; 39: 1041-52.
22. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994; 121: 241-6.
23. Kune GA, Kune S, Watson LF. Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res 1988; 48: 4399-404.
24. Muscat JE, Stellman SD, Wynder EL. Nonsteroidal antiinflammatory drugs and colorectal cancer. Cancer 1994; 74: 1847-54.
25. Smalley W, Ray WA, Daugherty J, Griffin MR. Use of non-steroidal anti-inflammatory drugs and incidence of colorectal cancer: a population-based study. Arch Intern Med 1999; 159: 161-6.
26. Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991; 325: 1593-6.
27. Janne PA, Mayer RJ. Chemoprevention of colorectal cancer. N Engl J Med 2000; 342: 1960-8.
28. Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer [erratum appears in N Engl J Med 2003; 348: 1939]. N Engl J Med 2003; 348: 883-90.
29. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003; 348: 891-9.
30. Benamouzig R, Deyra J, Martin A, et al. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology 2003; 125: 328-36.
31. Imperiale TF. Aspirin and the prevention of colorectal cancer. N Engl J Med 2003; 348: 879-80.
32. Bedi A, Pasricha PJ, Akhtar AJ, et al. Inhibition of apoptosis during development of colorectal cancer. Cancer Res 1995; 55: 1811-6.
33. Chan TA. Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemoprevention. Lancet Oncol 2002; 3: 166-74.
34. Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 1996; 271: 33 157-60.
35. Ota S, Bamba H, Kato A, Kawamoto C, Yoshida Y, Fujiwara K. Review article: COX-2, prostanoids and colon cancer. Aliment Pharmacol Ther 2002; 16: Suppl. 6.
36. Cao Y, Pearman AT, Zimmerman GA, McIntyre TM, Prescott SM. Intracellular unesterified arachidonic acid signals apoptosis. Proc Natl Acad Sci 2000; 97: 11 280-5.
37. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342: 1946-52.
38. Gwyn K, Sinicrope FA. Chemoprevention of colorectal cancer. Am J Gastroenterol 2002; 97: 13-21.
39. Ladabaum U, Scheiman JM, Fendrick AM. Potential effect of cyclooxygenase-2-specific inhibitors on the prevention of colorectal cancer: a cost-effectiveness analysis. Am J Med 2003; 114: 546-54.
40. Arguedas MR, Heudebert GR, Wilcox CM. Surveillance colonoscopy or chemoprevention with COX-2 inhibitors in average-risk post-polypectomy patients: a decision analysis. Aliment Pharmacol Ther 2001; 15: 631-8.
41. Bigler J, Whitton J, Lampe JW, Fosdick L, Bostick RM, Potter JD. CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk. Cancer Res 2001; 61: 3566-9.
42. Desai AA, Innocenti F, Ratain MJ. UGT pharmacogenomics: implications for cancer risk and cancer therapeutics. Pharmacogenetics 2003; 13: 517-23.
43. Ciotti M, Marrone A, Potter C, Owens IS. Genetic polymorphism in the human UGT1A6 (planar phenol) UDP-glucuronosyltransferase: pharmacological implications. Pharmacogenetics 1997; 7: 485-95.
44. Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data [erratum appears in Pharmacogenetics 2002; 12: 343]. Pharmacogenetics 2002; 12: 251-63.
45. Kirchheiner J, Stormer E, Meisel C, Steinbach N, Roots I, Brockmoller J. Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites. Pharmacogenetics 2003; 13: 473-80.
46. Goel A, Boland CR, Chauhan DP. Specific inhibition of cyclooxygenase-2 (COX-2) expression by dietary curcumin in HT-29 human colon cancer cells. Cancer Lett 2001; 172: 111-8.
47. Subbaramaiah K, Michaluart P, Chung WJ, Tanabe T, Telang N, Dannenberg AJ. Resveratrol inhibits cyclooxygenase-2 transcription in human mammary epithelial cells. Ann NY Acad Sci 1999; 889: 214-23.
48. Dommels YE, Raring MM, Keestra NG, Alink GM, van Bladeren PJ, van Ommen B. The role of cyclooxygenase in n-6 and n-3 polyunsaturated fatty acid mediated effects on cell proliferation, PGE(2) synthesis and cytotoxicity in human colorectal carcinoma cell lines. Carcinogenesis 2003; 24: 385-92.
49. Anti M, Armuzzi A, Morini S, et al. Severe imbalance of cell proliferation and apoptosis in the left colon and in the rectosigmoid tract in subjects with a history of large adenomas. Gut 2001; 48: 238-46.
50. Kato T, Hancock RL, Mohammadpour H, et al. Influence of omega-3 fatty acids on the growth of human colon carcinoma in nude mice. Cancer Lett 2002; 187: 169-77.
51. GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico [erratum appears in Lancet 2001; 357: 642]. Lancet 1999; 354: 447-55.
52. Giovannucci E, Stampfer MJ, Colditz GA, et al. Multivitamin use, folate, and colon cancer in women in the Nurses' Health Study. Ann Intern Med 1998; 129: 517-24.
53. Terry P, Jain M, Miller AB, Howe GR, Rohan TE. Dietary intake of folic acid and colorectal cancer risk in a cohort of women. Int J Cancer 2002; 97: 864-7.
54. La Vecchia C, Negri E, Pelucchi C, Franceschi S. Dietary folate and colorectal cancer. Int J Cancer 2002; 102: 545-7.
55. Fuchs CS, Willet WC, Colditz GA, et al. The influence of folate and multivitamin use on the familial risk of colon cancer in women. Cancer Epidemiol Biomark Prev 2002; 11: 227-34.
56. Duthie SJ. Folic acid deficiency and cancer: mechanisms of DNA instability. Br Med Bull 1999; 55: 578-92.
57. 7 Pufulete M, Al Ghnaniem R, Leather AJ, et al. Folate status, genomic DNA hypomethylation, and risk of colorectal adenoma and cancer: a case control study. Gastroenterology 2003; 124: 1240-8.
58. Little J, Sharp L. Colorectal neoplasia and genetic polymorphisms associated with folate metabolism. Eur J Cancer Prev 2002; 11: 105-10.
59. Rozen R. Genetic predisposition to hyperhomocysteinemia: deficiency of methylenetetrahydrofolate reductase (MTHFR). Thromb Haemost 1997; 78: 523-6.
60. Lamprecht SA, Lipkin M. Chemoprevention of colon cancer by calcium, vitamin D and folate: molecular mechanisms. Nature Rev Cancer 2003; 3: 601-14.
61. Ma J, Stampfer MJ, Giovannucci E, et al. Methylenetetrahydrofolate reductase polymorphism, dietary interactions, and risk of colorectal cancer. Cancer Res 1997; 57: 1098-102.
62. Chen J, Giovannucci E, Kelsey K, et al. A methylenetetrahydrofolate reductase polymorphism and the risk of colorectal cancer. Cancer Res 1996; 56: 4862-4.
63. Park KS, Mok JW, Kim JC. The 677C → T mutation in 5,10-methylenetetrahydrofolate reductase and colorectal cancer risk. Genet Test 1999; 3: 233-6.
64. Slattery ML, Potter JD, Samowitz W, Schaffer D, Leppert M. Methylenetetrahydrofolate reductase, diet, and risk of colon cancer. Cancer Epidemiol Biomark Prev 1999; 8: 513-8.
65. Chen J, Giovannucci E, Hankinson SE, et al. A prospective study of methylenetetrahydrofolate reductase and methionine synthase gene polymorphisms, and risk of colorectal adenoma. Carcinogenesis 1998; 19: 2129-32.
66. Marugame T, Tsuji E, Inoue H, et al. Methylenetetrahydrofolate reductase polymorphism and risk of colorectal adenomas. Cancer Lett 2000; 151: 181-6.
67. Ulrich CM, Kampman E, Bigler J, et al. Colorectal adenomas and the C677T MTHFR polymorphism: evidence for gene-environment interaction? Cancer Epidemiol Biomark Prev 1999; 8: 659-68.
68. Giovannucci E, Stampfer MJ, Colditz G, Rimm EB, Willett WC. Relationship of diet to risk of colorectal adenoma in men. J Natl Cancer Inst 1992; 84: 91-8.
69. Willett WC, Stampfer MJ, Colditz GA, Rosner BA, Speizer FE. Relation of meat, fat, and fiber intake to the risk of colon cancer in a prospective study among women. N Engl J Med 1990; 323: 1664-72.
70. Nagengast FM, Grubben MJ, van Munster IP. Role of bile acids in colorectal carcinogenesis. Eur J Cancer 1995; 31A: 1067-70.
71. Newmark HL, Wargovich MJ, Bruce WR. Colon cancer and dietary fat, phosphate, and calcium: a hypothesis. J Natl Cancer Inst 1984; 72: 1323-5.
72. Baron JA, Beach M, Mandel JS, et al. Calcium supplements for the prevention of colorectal adenomas. Calcium Polyp Prevention Study Group. N Engl J Med 1999; 340: 101-7.
73. Bonithon-Kopp C, Kronborg O, Giacosa A, Rath U, Faivre J. Calcium and fibre supplementation in prevention of colorectal adenoma recurrence: a randomised intervention trial. European Cancer Prevention Organisation Study Group. Lancet 2000; 356: 1300-6.
74. Wu K, Willett WC, Fuchs CS, Colditz GA, Giovannucci EL. Calcium intake and risk of colon cancer in women and men. J Natl Cancer Inst 2002; 94: 437-46.
75. Pardi DS, Loftus EV Jr, Kremers WK, Keach J, Lindor KD. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003; 124: 889-93.
76. Serfaty L, De Leusse A, Rosmorduc O, et al. Ursodeoxycholic acid therapy and the risk of colorectal adenoma in patients with primary biliary cirrhosis: an observational study. Hepatology 2003; 38: 203-9.
77. Hill MJ, Melville DM, Lennard-Jones JE, Neale K, Ritchie JK. Faecal bile acids, dysplasia, and carcinoma in ulcerative colitis. Lancet 1987; 2: 185-6.
78. Bayerdorffer E, Mannes GA, Richter WO, et al. Increased serum deoxycholic acid levels in men with colorectal adenomas. Gastroenterology 1993; 104: 145-51.
79. Bayerdorffer E, Mannes GA, Ochsenkuhn T, Dirschedl P, Wiebecke B, Paumgartner G. Unconjugated secondary bile acids in the serum of patients with colorectal adenomas. Gut 1995; 36: 268-73.
80. Ochsenkuhn T, Bayerdorffer E, Meining A, et al. Colonic mucosal proliferation is related to serum deoxycholic acid levels. Cancer 1999; 85: 1664-9.
81. Batta AK, Salen G, Holubec H, Brasitus TA, Alberts D, Earnest DL. Enrichment of the more hydrophilic bile acid ursodeoxycholic acid in the fecal water-soluble fraction after feeding to rats with colon polyps. Cancer Res 1998; 58: 1684-7.
82. Rodrigues CM, Kren BT, Steer CJ, Setchell KD. The site-specific delivery of ursodeoxycholic acid to the rat colon by sulfate conjugation. Gastroenterology 1995; 109: 1835-44.
83. Brentnall TA. Ursodiol: good drug makes good. Gastroenterology 2003; 124: 1139-40.
84. Kim YI. AGA technical review: impact of dietary fiber on colon cancer occurrence. Gastroenterology 2000; 118: 1235-57.
85. Howe GR, Benito E, Castelleto R, et al. Dietary intake of fiber and decreased risk of cancers of the colon and rectum: evidence from the combined analysis of 13 case-control studies. J Natl Cancer Inst 1992; 84: 1887-96.
86. Fuchs CS, Giovannucci EL, Colditz GA, et al. Dietary fiber and the risk of colorectal cancer and adenoma in women. N Engl J Med 1999; 340: 169-76.
87. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC. Intake of fat, meat, and fiber in relation to risk of colon cancer in men. Cancer Res 1994; 54: 2390-7.
88. Steinmetz KA, Kushi LH, Bostick RM, Folsom AR, Potter JD. Vegetables, fruit, and colon cancer in the Iowa Women's Health Study. Am J Epidemiol 1994; 139: 1-15.
89. Alberts DS, Martinez ME, Roe DJ, et al. Lack of effect of a high-flber cereal supplement on the recurrence of colorectal adenomas. Phoenix Colon Cancer Prevention Physicians' Network. N Engl J Med 2000; 342: 1156-62.
90. MacLennan R, Macrae F, Bain C, et al. Randomized trial of intake of fat, fiber, and beta carotene to prevent colorectal adenomas. The Australian Polyp Prevention Project. J Natl Cancer Inst 1995; 87: 1760-6.
91. McKeown-Eyssen GE, Bright-See E, Bruce WR, et al. A randomized trial of a low fat high fibre diet in the recurrence of colorectal polyps. Toronto Polyp Prevention Group [erratum appears in J Clin Epidemiol 1995; 48(2): i]. J Clin Epidemiol 1994; 47: 525-36.
92. Schatzkin A, Lanza E, Corle D, et al. Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. Polyp Prevention Trial Study Group. N Engl J Med 2000; 342: 1149-55.
93. Bingham SA, Day NE, Luben R, et al. Dietary fibre in food and protection against colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC): an observational study. Lancet 2003; 361: 1496-501.
94. Peters U, Sinha R, Chatterjee N, et al. Dietary fibre and colorectal adenoma in a colorectal cancer early detection programme. Lancet 2003; 361: 1491-5.
95. Jacobs ET, Giuliano AK, Roe DJ, et al. Intake of supplemental and total fiber and risk of colorectal adenoma recurrence in the wheat bran fiber trial [erratum appears in Cancer Epidemiol Biomark Prev 2002; 11: 1699]. Cancer Epidemiol Biomark Prev 2002; 11: 906-14.
96. Terry P, Giovannucci E, Michels KB, et al. Fruit, vegetables, dietary fiber, and risk of colorectal cancer. J Natl Cancer Inst 2001; 93: 525-33.
97. Rhodes JM. Unifying hypothesis for inflammatory bowel disease and associated colon cancer: sticking the pieces together with sugar. Lancet 1996; 347: 40-4.
98. Campbell BJ, Finnie IA, Hounsell EF, Rhodes JM. Direct demonstration of increased expression of Thomsen-Friedenreich (TF) antigen in colonic adenocarcinoma and ulcerative colitis mucin and its concealment in normal mucin. J Clin Invest 1995; 95: 571-6.
99. Evans RC, Fear S, Ashby D, et al. Diet and colorectal cancer: an investigation of the lectin/galactose hypothesis. Gastroenterology 2002; 122: 1784-92.
100. Rhodes JM. Lectins, colitis and colon cancer. J R Coll Physicians Lond 2000; 34: 191-6.
101. Ryder SD, Jacyna MR, Levi AJ, Rizzi PM, Rhodes JM. Peanut ingestion increases rectal proliferation in individuals with mucosal expression of peanut lectin receptor. Gastroenterology 1998; 114: 44-9.
102. Ritter CA, Arteaga CL. The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors. Semin Oncol 2003; 30: Suppl. 11.
103. O'dwyer PJ, Benson AB III. Epidermal growth factor receptor-targeted therapy in colorectal cancer. Semin Oncol 2002; 29: Suppl. 7.
104. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Haematol 1995; 19: 183-232.
105. Arteaga CL. Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin Oncol 2002; 29: Suppl. 9.
106. Sirotnak FM. Studies with ZD1839 in preclinical models. Semin Oncol 2003; 30; Suppl. 20.
107. Dancey JE, Freidlin B. Targeting epidermal growth factor receptor - are we missing the mark?. Lancet 2003; 362: 62-4.
108. Douglass EC. Development of ZD1839 in colorectal cancer. Semin Oncol 2003; 30: Suppl. 22.
109. Torrance CJ, Jackson PE, Montgomery E, et al Combinatorial chemoprevention of intestinal neoplasia. Nature Med 2000; 6: 1024-8.
110. Schiller JH. New directions for ZD1839 in the treatment of solid tumors. Semin Oncol 2003; 30: Suppl. 55.
111. Marciniak DJ, Moragoda L, Mohammad RM, et al. Epidermal growth factor receptor-related protein: a potential therapeutic agent for colorectal cancer. Gastroenterology 2003; 124: 1337-47.
112. Tabor CW, Tabor H. Polyamines. Annu Rev Biochem 1984; 53: 749-90.
113. Pegg AE, McCann PP. Polyamine metabolism and function. Am J Physiol 1982; 243: C212-21.
114. Saydjari R, Townsend CM Jr, Barranco SC, Thompson JC. Polyamines in gastrointestinal cancer. Dig Dis Sci 1989; 34: 1629-36.
115. Luk GD, Baylin SB. Ornithine decarboxylase as a biologic marker in familial colonic polyposis. N Engl J Med 1984; 311: 80-3.
116. Giardiello FM, Hamilton SR, Hylind LM, Yang VW, Tamez P, Casero RA Jr. Ornithine decarboxylase and polyamines in familial adenomatous polyposis. Cancer Res 1997; 57: 199-201.
117. Berdinskikh NK, Ignatenko NA, Zaletok SP, Ganina KP, Chorniy VA. Ornithine decarboxylase activity and polyamine content in adenocarcinomas of human stomach and large intestine. Int J Cancer 1991; 47: 496-8.
118. Hixson LJ, Garewal HS, McGee DL, et al. Ornithine decarboxylase and polyamines in colorectal neoplasia and mucosa. Cancer Epidemiol Biomark Prev 1993; 2: 369-74.
119. LaMuraglia GM, Lacaine F, Malt RA. High ornithine decarboxylase activity and polyamine levels in human colorectal neoplasia. Ann Surg 1986; 204: 89-93.
120. Lawson MJ, White LM, Coyle P, Butler RN, Roberts-Thomson IC, Conyers RA. An assessment of proliferative and enzyme activity in transitional mucosa adjacent to colonie cancer. Cancer 1989; 64: 1061-6.
121. Linsalata M, Russo F, Cavallini A, Berloco P, Di Leo A. Polyamines, diamine oxidase, and ornithine decarboxylase activity in colorectal cancer and in normal surrounding mucosa. Dis Colon Rectum 1993; 36: 662-7.
122. Narisawa T, Takahashi M, Niwa M, et al. Increased mucosal ornithine decarboxylase activity in large bowel with multiple tumors, adenocarcinoma, and adenoma. Cancer 1989; 63: 1572-6.
123. Porter CW, Herrera-Ornelas L, Pera P, Petrelli NF, Mittelman A. Polyamine biosynthetic activity in normal and neoplastic human colorectal tissues. Cancer 1987; 60: 1275-81.
124. Rozhin J, Wilson PS, Bull AW, Nigro ND. Ornithine decarboxylase activity in the rat and human colon. Cancer Res 1984; 44: 3226-30.
125. Freitas D, Goulao MH, Camacho E, et al. Clinical relevance of proliferation biomarkers and p53 expression in rectal mucosa and sporadic colonie adenomas: a prospective study. Hepato-Gastroenterology 2002; 49: 1269-74.
126. Pegg AE. Polyamine metabolism and its importance in neoplastic growth and a target for chemotherapy. Cancer Res 1988; 48: 759-74.
127. Abeloff MD, Slavik M, Luk GD, et al. Phase I trial and pharmacokinetic studies of alpha-difluoromethylornithine - an inhibitor of polyamine biosynthesis. J Clin Oncol 1984; 2: 124-30.
128. Love RR, Carbone PP, Verma AK, et al. Randomized phase I chemoprevention dose-seeking study of alpha-difluoromethylornithine, J Natl Cancer Inst 1993; 85: 732-7.
129. Meyskens FL Jr, Gerner EW, Emerson S, et al. Effect of alpha-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention. J Natl Cancer Inst 1998; 90: 1212-8.
130. Jacoby RF, Cole CE, Tutsch K, et al. Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Ape mutant Min mouse adenomas, and selective toxicity against Ape mutant embryos. Cancer Res 2000; 60: 1864-70.
131. Rao CV, Tokumo K, Rigotty J, Zang E, Kelloff G, Reddy BS. Chemoprevention of colon carcinogenesis by dietary administration of piroxicam, alpha-difluoromethylornithine, 16-alpha-fluoro-5-androsten-17-one, and ellagic acid individually and in combination. Cancer Res 1991; 51: 4528-34.
132. Reddy BS, Nayini J, Tokumo K, Rigotty J, Zang E, Kelloff G. Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal antiinflammatory drug, with D,1-alpha- difluoromethylornithine, an ornithine decarboxylase inhibitor, in diet. Cancer Res 1990; 50: 2562-8.
133. Parker MT, Gerner EW. Polyamine-mediated post-transcriptional regulation of COX-2. Biochimie 2002; 84: 815-9.
134. Bello-Fernandez C, Packham G, Cleveland JL. The ornithine decarboxylase gene is a transcriptional target of c-Myc. Proc Natl Acad Sci 1993; 90: 7804-8.
135. Augenlicht LH, Wadler S, Corner G, et al. Low-level c-myc amplification in human colonie carcinoma cell lines and tumors: a frequent, p53-independent mutation associated with improved outcome in a randomized multi-institutional trial. Cancer Res 1997; 57: 1769-75.
136. He TC, Sparks AB, Rago C, et al. Identification of c-MYC as a target of the APC pathway. Science 1998; 281: 1509-12.
137. Guo Y, Harris RB, Rosson D, Boorman D, O'Brien TG. Functional analysis of human ornithine decarboxylase alleles. Cancer Res 2000; 60: 6314-7.
138. Martinez ME, O'Brien TG, Fultz KE, et al. Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene. Proc Natl Acad Sci 2003; 100: 7859-64.
139. Rayman MP. Dietary selenium: time to act. Br Med J 1997; 314: 387-8.
140. Rayman MP. The importance of selenium to human health. Lancet 2000; 356: 233-41.
141. Ganther HE. Selenium metabolism, selenoproteins and mechanisms of cancer prevention: complexities with thioredoxin reductase. Carcinogenesis 1999; 20: 1657-66.
142. Becker K, Gromer S, Schirmer RH, Muller S. Thioredoxin reductase as a pathophysiological factor and drug target. Eur J Biochem 2000; 267: 6118-25.
143. Reddy BS, The Fourth DeWitt S, Goodman lecture. Novel approaches to the prevention of colon cancer by nutritional manipulation and chemoprevention. Cancer Epidemiol Biomark Prev 2000; 9: 239-47.
144. Seo YR, Kelley MR, Smith ML. Selenomethionine regulation of p53 by a ref1-dependent redox mechanism. Proc Natl Acad Sci 2002; 99: 14 548-53.
145. Anestal K, Arner ES. Rapid induction of cell death by selenium-compromised thioredoxin reductase 1 but not by the fully active enzyme containing selenocysteine. J Biol Chem 2003; 278: 15 966-72.
146. Clark LC, Combs GF Jr, Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group [erratum appears in J Am Med Assoc 1997; 277: 1520]. J Am Med Assoc 1996; 276: 1957-63.
147. Early DS, Hill K, Burk R, Palmer I. Selenoprotein levels in patients with colorectal adenomas and cancer. Am J Gastroenterol 2002; 97: 745-8.
148. Fernandez-Banares F, Cabre E, Esteve M, et al. Serum selenium and risk of large size colorectal adenomas in a geographical area with a low selenium status. Am J Gastroenterol 2002; 97: 2103-8.
149. Psathakis D, Wedemeyer N, Oevermann E, Krug F, Siegers CP, Bruch HP. Blood selenium and glutathione peroxidase status in patients with colorectal cancer. Dis Colon Rectum 1998; 41: 328-35.
150. Office for National Statistics. Mortality Statistics: Cause. England and Wales 2001. Series DH2 No. 28. London: Office for National Statistics, 2002.
151. Corley DA, Kerlikowske K, Verma R, Buffler P. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 2003; 124: 47-56.
152. Bosetti C, Gallus S, La Vecchia C. Aspirin and cancer risk: an update to 2001. Eur J Cancer Prev 2002; 11: 535-42.
153. Lauer MS. Clinical practice. Aspirin for primary prevention of coronary events. N Engl J Med 2002; 346: 1468-74.
154. Hart RG, Halperin JL, McBride R, Benavente O, Man-Son-Hing M, Kronmal RA. Aspirin for the primary prevention of stroke and other major vascular events: meta-analysis and hypotheses. Arch Neurol 2000; 57: 326-32.
155. Tanasescu M, Leitzmann MF, Rimm EB, Willett WC, Stampfer MJ, Hu FB. Exercise type and intensity in relation to coronary heart disease in men. J Am Med Assoc 2002; 288: 1994-2000.
156. Hu FB, Stampfer MJ, Colditz GA, et al. Physical activity and risk of stroke in women. J Am Med Assoc 2000; 283: 2961-7.
157. Batty GD, Lee IM. Physical activity for preventing strokes. Br Med J 2002; 325: 350-1.
158. Potter JD. Colorectal cancer: molecules and populations. J Natl Cancer Inst 1999; 91: 916-32.
159. Slattery ML, Potter JD. Physical activity and colon cancer: confounding or interaction? Med Sci Sports Exercise 2002; 34: 913-9.
160. Slattery ML, Edwards S, Curtin K, et al. Physical activity and colorectal cancer. Am J Epidemiol 2003; 158: 214-24.
161. White C. Cancer rates in Europe are linked to overweight, experts warn. Br Med J 2003; 327: 700.
162. Hu FB, Willett WC. Optimal diets for prevention of coronary heart disease. J Am Med Assoc 2002; 288: 2569-78.
163. Iso H, Rexrode KM, Stampfer MJ, et al. Intake of fish and omega-3 fatty acids and risk of stroke in women. J Am Med Assoc 2001; 285: 304-12.
164. He K, Rimm EB, Merchant A, et al. Fish consumption and risk of stroke in men. J Am Med Assoc 2002; 288: 3130-6.
165. Cummings JH, Bingham SA. Diet and the prevention of cancer. Br Med J 1998; 317: 1636-40.